Development of a scale down cell culture model using multivariate analysis as a qualification tool

Biotechnology Progress

Volumn 30, Issue 1, 2014, Pages 152-160

  Tsang, Valerie Liu ^a   Wang, Angela X ^a   Yusuf Makagiansar, Helena ^a   Ryll, Thomas ^a  

^a BIOGEN   (United States)

Author keywords

Bioreactor scaling; Multivariate analysis; Process characterization; Quality by design; Scale down model

Indexed keywords

CELL CULTURE PROCESS; DISSOLVED CARBON DIOXIDE; GEOMETRIC DIFFERENCE; MEASURABLE PARAMETERS; MULTI VARIATE ANALYSIS; PROCESS CHARACTERIZATION; QUALITY BY DESIGNS; SCALE DOWN MODEL;

BIOREACTORS; CARBON DIOXIDE; DESIGN; MANUFACTURE; MONOCLONAL ANTIBODIES; MULTIVARIANT ANALYSIS; PHYSIOLOGICAL MODELS; TOOLS;

CELL CULTURE;

MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOREACTOR; BIOTECHNOLOGY; CHO CELL LINE; CRICETULUS; CULTURE TECHNIQUE; EQUIPMENT; HAMSTER; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHO CELLS; CRICETINAE; CRICETULUS; LEAST-SQUARES ANALYSIS; MULTIVARIATE ANALYSIS; RECOMBINANT PROTEINS;

EID: 84893794827     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1819     Document Type: Article

References (34)

1. FDA, Guidance for Industry PAT-a framework for innovative pharmaceutical development, manufacturing, and quality assurance. In: FDA, U. S. D. o. H. a. H. S., Ed.; 2004.
2. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26-34.
3. Kourti T. The process analytical technology initiative and multivariate process analysis, monitoring and control. Anal Bioanal Chem. 2006;384:1043-1048.
4. CMC_Biotech_Working_Group. A-Mab: a case study in bioprocess development. http://www.casss.org/associations/9165/files/A-Mab_Case_Study_Version_2-1.pdf; 2009.
5. Marks DM. Equipment design considerations for large scale cell culture. Cytotechnology 2003;42:21-33.
6. Yang JD, Lu C, Stasny B, Henley J, Guinto W, Gonzalez C, Gleason J, Fung M, Collopy B, Benjamino M, Gangi J, Hanson M, Ille E. Fed-batch bioreactor process scale-up from 3-L to 2, 500-L scale for monoclonal antibody production from cell culture. Biotechnol Bioeng. 2007;98:141-154.
7. Nienow AW. Reactor engineering in large scale animal cell culture. Cytotechnology 2006;50:9-33.
8. Xing Z, Kenty BM, Li ZJ, Lee SS. Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnol Bioeng. 2009;103:733-746.
9. Li F, Hashimura Y, Pendleton R, Harms J, Collins E, Lee B. A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol Prog. 2006;22:696-703.
10. Harmsen M, Stofferis J, Malphettes L. Development and fine-tuning of a scale down model for process characterization studies of a monoclonal antibody upstream production process. BMC Proc. 2011;5(Suppl 8):P70.
11. Rathore A, Krishnan R, Tozer S, Smiley D, Rausch S, Seely J. Scaling down of biopharmaceutical unit operations - Part I: Fermentation. BioPharm Int. 2005;18:60-68.
12. Abu-Absi SF, Yang L, Thompson P, Jiang C, Kandula S, Schilling B, Shukla AA. Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng. 2010;106:894-905.
13. Rouiller Y, Solacroup T, Deparis V, Barbafieri M, Gleixner R, Broly H, Eon-Duval A. Application of quality by design to the characterization of the cell culture process of an Fc-fusion protein. Eur J Pharm Biopharm. 2012;81:426-437.
14. Banerjee A, Ma NN, Ramasubramanyan N. Designing in quality: approaches to defining the design space for a monoclonal antibody process. BioPharm Int. 2010;23:26-40.
15. Farrell P, Sun J, Gao M, Sun H, Pattara B, Zeiser A, D'Amore T. Development of a scaled-down aerobic fermentation model for scale-up in recombinant protein vaccine manufacturing. Vaccine 2012;30:5695-5698.
16. Undey C, Tatara E, Cinar A. Intelligent real-time performance monitoring and quality prediction for batch/fed-batch cultivations. J Biotechnol. 2004;108:61-77.
17. Kirdar AO, Green KD, Rathore AS. Application of multivariate data analysis for identification and successful resolution of a root cause for a bioprocessing application. Biotechnol Prog. 2008;24:720-726.
18. Kirdar AO, Conner JS, Baclaski J, Rathore AS. Application of multivariate analysis toward biotech processes: case study of a cell-culture unit operation. Biotechnol Prog. 2007;23:61-67.
19. Gabrielsson J, Lindberg NO, Lundstedt T. Multivariate methods in pharmaceutical applications. J Chemometr. 2002;16:141-160.
20. Le H Kabbur S Pollastrini L Sun Z Mills K Johnson K Karypis G Hu WS. Multivariate analysis of cell culture bioprocess data-lactate consumption as process indicator. J Biotechnol. 2012;162:210-223.
21. Glassey J. Multivariate data analysis for advancing the interpretation of bioprocess measurement and monitoring data. In: Mandenius CF, TitchenerHooker NJ, editors. Measurement, Monitoring, Modelling and Control of Bioprocesses. Berlin, Germany: Springer Berlin Heidelberg; 2013; Vol. 132, pp 167-191.
22. Xing Z, Li Z, Chow V, Lee SS. Identifying inhibitory threshold values of repressing metabolites in CHO cell culture using multivariate analysis methods. Biotechnol Prog. 2008;24:675-683.
23. Pieracci J, Yusuf-Makagiansar H. Leveraging multivariate analysis tools to qualify scaled-down models. In: Rathore AS, Sofer G, editors. Process Validation in Manufacturing of Biopharmaceuticals, 3rd ed.; Boca Raton, FL: CRC Press; 2012; pp 411-440.
24. Heath C, Kiss R. Cell culture process development: advances in process engineering. Biotechnol Prog. 2007;23:46-51.
25. Julien C, Whitford W. Bioreactor monitoring, modeling, and simulation. BioProc Int. 2007;5:10-17.
26. van Hoek P, Harms J, Wang X, Rathore AS. Case study on definition of process design space for a microbial fermentation step. In: Rathore AS, Mhatre R, editors. Quality by Design for Biopharmaceuticals. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2008; pp 85-109.
27. Godavarti R, Petrone J, Robinson J, Wright R, Kelley BD. Scale-down models for purification processes: approaches and applications. Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies, Vol. 29; 2005:69-142.
28. Eriksson LJE, Kettaneh-Wold N, Wold S. Multi- and Megavariate Data Analysis Principles and Applications, 1st ed. Umea, Sweden: Umetrics; 2001.
29. 2 and osmolality on hybridoma cells: growth, metabolism and monoclonal antibody production. Cytotechnology 1998;28:213-227.
30. Mostafa SS, Gu X. Strategies for Improved dCO2 removal in large-scale fed-batch cultures. Biotechnol Prog. 2003;2003:45-51.
31. Kimura R, Miller WM. Glycosylation of CHO-derived recombinant tPA produced under elevated pCO2. Biotechnol Prog. 1997;13:311-317.
32. deZengotita VM, Schmelzer AE, Miller WM. Characterization of hybridoma cell responses to elevated pCO(2) and osmolality: intracellular pH, cell size, apoptosis, and metabolism. Biotechnol Bioeng. 2002;77:369-380.
33. Schmelzer AE, Miller WM. Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog. 2002;18:346-353.
34. 2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol Prog. 2005;21:70-77.